Leerink Partners initiated coverage of Absci Corporation on June 4, 2024, assigning the company an Outperform rating [1].

The move signals growing institutional confidence in the intersection of artificial intelligence and drug discovery. As biotechnology firms increasingly rely on AI to shorten development timelines, Leerink's endorsement provides a valuation benchmark for Absci's specific approach to protein design.

The investment bank established a price target of $12 for the NASDAQ-listed company [1]. Following the announcement, Absci shares rose 8.08% [4]. This surge pushed the stock to its highest level in more than four years [5].

Analysts at Leerink said the company's AI-focused drug pipeline is a primary driver for the positive outlook [2]. The bank also said upcoming catalyst events could further influence the company's valuation [2].

Absci Corporation operates at the forefront of generative AI for antibody discovery. By utilizing a proprietary platform, the company aims to design new medicines from scratch rather than relying on traditional screening methods. The Outperform rating suggests that Leerink expects the stock to beat the broader market, or its peer group, in the near term [1].

Market reaction to the coverage was immediate, reflecting a broader trend of volatility and opportunity within the AI-driven science sector. The $12 target represents a significant projection of growth based on the company's current developmental trajectory [1].

“Leerink established a price target of $12 for the NASDAQ-listed company.”

The initiation of coverage by a specialized investment bank like Leerink provides Absci with critical institutional validation. By linking the stock's potential to 'catalyst events' and an AI-driven pipeline, the market is shifting its valuation of biotech firms away from current revenue and toward the theoretical efficiency of their AI platforms. This suggests that the biotech sector is entering a phase where software capabilities are as influential as clinical trial data.